| Date | Time | Room | Session Title | Presentation Time | Topic | Role |
|---|---|---|---|---|---|---|
| 14/04/2023 | 13:20 to 13:45 | Golden Hall |
Plenary Lecture - Bladder Module - Session: Metastatic Disease |
13:20 to 13:40 | Updates on antibody-drug conjugates for urothelial cancer | Speaker |
| 14/04/2023 | 13:20 to 13:45 | Golden Hall |
Plenary Lecture - Bladder Module - Session: Metastatic Disease |
13:40 to 13:45 | Discussion | Discussant |
| 14/04/2023 | 16:20 to 17:20 | Golden Hall |
Plenary Lecture - Clinical cases discussion: bladder cancer |
Discussant | ||
| 15/04/2023 | 10:50 to 12:10 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
11:05 to 11:20 | How to choose first-line treatment for metastatic renal cell carcinoma? I support the combination of IO + IO | Speaker |
| 15/04/2023 | 10:50 to 12:10 | Golden Hall |
Plenary Lecture - Kidney Module - Session: Metastatic Disease |
11:20 to 11:25 | Discussion | Discussant |
| 15/04/2023 | 13:00 to 13:40 | Golden Hall |
Plenary Lecture - Clinical cases discussion: metastatic kidney cancer |
Discussant |